STOCK TITAN

PepGen Inc. - $PEPG STOCK NEWS

Welcome to our dedicated page for PepGen news (Ticker: $PEPG), a resource for investors and traders seeking the latest updates and insights on PepGen stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PepGen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PepGen's position in the market.

Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) appoints Howard Mayer, M.D. to its Board of Directors. Dr. Mayer brings extensive clinical development and regulatory experience to the company, enhancing its mission to revolutionize genetic therapies for severe neuromuscular and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
management
-
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG) reported Q3 2023 financial results, highlighting progress in clinical trials for neuromuscular and neurological diseases. Recent developments include FDA clearance for FREEDOM-DM1 study, Orphan Drug Designation, and CONNECT1-EDO51 advancements. The company ended Q3 2023 with $129.5 million in cash and cash equivalents, expected to fund operations into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.4%
Tags
-
Rhea-AI Summary
PepGen Inc. receives FDA clearance to initiate the FREEDOM-DM1 Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1) in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
Rhea-AI Summary
PepGen Inc. will be presenting at the 28th Annual Congress of the World Muscle Society, showcasing their advancements in oligonucleotide therapies for neuromuscular diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences
-
Rhea-AI Summary
PepGen receives FDA orphan drug designation for PGN-EDODM1 to treat myotonic dystrophy type 1
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
-
Rhea-AI Summary
PepGen announces key highlights from upcoming presentations on their EDO platform for oligonucleotide therapies. EDO technology enables higher level of nuclear delivery of oligonucleotides, with 72% of muscle nuclei positive for oligonucleotide in non-human primates. PGN-EDODM1 corrected 99% of mis-splicing and reversed 99% of myotonia in a murine model. Positive potential for transforming treatment of severe neuromuscular and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
none
-
Rhea-AI Summary
PepGen Inc. reported financial results for Q2 2023, ending with $147.0 million in cash and cash equivalents. They plan to initiate the Phase 2 CONNECT2-EDO51 study in the second half of 2023. The company is pursuing a global strategy for the Phase 1 FREEDOM-EDODM1 study and working to lift the clinical hold in the U.S. They expect to report initial dystrophin production, exon skipping, and safety data from the CONNECT1 study in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.99%
Tags
PepGen Inc.

Nasdaq:PEPG

PEPG Rankings

PEPG Stock Data

453.14M
16.89M
0.05%
76.67%
1.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOSTON